Evolving Calciphylaxis—What Randomized, Controlled Trials Can Contribute to the Capture of Rare Diseases | Zendy

Markus Ketteler | Zendy; Patrick Biggar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolving Calciphylaxis—What Randomized, Controlled Trials Can Contribute to the Capture of Rare Diseases

Author(s) -

Markus Ketteler,

Patrick Biggar

Publication year - 2015

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03350315

Subject(s) - calciphylaxis , medicine , cinacalcet , secondary hyperparathyroidism , population , surgery , hemodialysis , dialysis , randomized controlled trial , disease , parathyroid hormone , environmental health , calcium

Calciphylaxis or calcific uremic arteriolopathy is a rare but disastrous and life-threatening disease mostly affecting patients on dialysis. It is characterized by very painful, ulcerating, and, finally, necrotic skin lesions ([Figure 1][1]), which in histology, show calcifications in the media of

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research